uploads/2016/07/Graph-5-2-1.png

What Do Analysts Recommend for United Therapeutics?

By

Updated

Analyst recommendations

Based on the recommendations of 14 brokerage firms in a Bloomberg survey, 23.1% of analysts gave United Therapeutics (UTHR) a “buy” recommendation while 69.2% of analysts rated the company a “hold.” Only 7.7% of the analysts rated United Therapeutics a “sell.” To learn more about the reduced analyst confidence and depressed valuation multiples for United Therapeutics, please refer to How Does United Therapeutics Compare with Peers on Valuation?

 

Article continues below advertisement

The consensus 12-month target price for United Therapeutics is ~$128.67, which represents a rise of approximately 16.2% from the stock’s last price of $110.86 on July 18, 2016. If the company’s share price manages to surpass this price target, it may also boost the iShares S&P Mid-Cap 400 Growth ETF (IJK). United Therapeutics makes up about 0.69% of IJK’s total portfolio.

Peer companies

Based on a Bloomberg survey of 14 broker firms, Ionis Pharmaceuticals (IONS) received “buy” recommendations from 38.5% of firms and “hold” recommendations from 53.8% of firms. Only 7.7% of firms have rated Ionis Pharmaceuticals as a “sell.” The consensus 12-month target price for Ionis Pharmaceuticals is ~$32.38, which represents a rise of 16.9% from the stock’s last price of $27.69 on July 18, 2016.

Among the 28 brokerage firms surveyed by Bloomberg for Regeneron (REGN), 51.9% gave it a “buy” while 44.4% gave it a “hold” recommendation. Only 3.7% of the surveyed firms rate Regeneron a “sell.” The consensus 12-month target price for Regeneron is ~$466.82, which represents a rise of 22.4% from the stock’s last price of $381.54 on July 18, 2016.

Based on the recommendations of 18 broker firms in a Bloomberg survey, Incyte (INCY) received “buy” recommendations from 88.9% of firms and “hold” recommendations from 11.1% of firms. None of the firms rated Incyte a “sell.” The consensus 12-month target price for Incyte is ~$92.20, which represents a rise of 9.6% from the stock’s closing price of $85.54 on July 18, 2016.

Advertisement

More From Market Realist